• Oncolytics Biotech reported initial preclinical findings showing pelareorep combined with RAS-targeted approaches outperformed either approach alone in a solid tumor model.
• The results have not been fully presented yet; full data are expected in fall or winter 2026.
• The company plans additional studies in pancreatic ductal adenocarcinoma and colorectal cancer to assess immune activation, response durability, and time-to-resistance.
• The work targets RAS-mutated tumors, positioning pelareorep as a potential immune-priming backbone for next-generation targeted therapy combinations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010900PRIMZONECNPR____9729300) on June 01, 2026, and is solely responsible for the information contained therein.